Relapse is common in multiple myeloma, leading to the approval of two cell therapies—Abecma and Carvykti—for earlier lines of treatment. Both therapies target the BCMA protein on multiple myeloma cells. While FDA advisory committees raised concerns about risks such as death, the benefits of these therapies were ultimately deemed to outweigh the risks, particularly for patients who have exhausted standard treatment options. The expanded approvals give hope to patients who experience relapse after multiple lines of therapy, with statistically significant improvements in progression-free survival reported in clinical trials. The FDA also made manufacturing improvements for Carvykti, enhancing its effectiveness for patients with advanced disease.
Source link
Cell Therapy Now Set to Reach More Patients With Expanded FDA Nod for 2 Multiple Myeloma Drugs
